AMGN

AMGEN TO PRESENT AT THE GOLDMAN SACHS 44TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

Retrieved on: 
Friday, June 9, 2023
AMGN, Goldman Sachs controversies, Webcast, Calendar, Goldman, Conference, Internet, Cryptocurrency, Broadcasting, Amgen

THOUSAND OAKS, Calif., June 9, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 44th Annual Global Healthcare Conference at 2:20 p.m.

Key Points: 
  • THOUSAND OAKS, Calif., June 9, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 44th Annual Global Healthcare Conference at 2:20 p.m.
  • Robert A. Bradway, chairman and chief executive officer at Amgen will present at the conference.
  • Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar.
  • The webcast will be archived and available for replay for at least 90 days after the event.

AMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH ACROSS ITS DIVERSE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2023

Retrieved on: 
Thursday, June 1, 2023
AMGN, KRAS, Amgen, KID, Osteoporosis, Research and development, Plasma, RAS, Patient, Panitumumab, Blinatumomab, Myelodysplastic syndrome, Carcinoma, CT, Bi-specific T-cell engager, Multiple myeloma, Panama, Lenalidomide, Lung cancer, MRD, Heath Robinson (codebreaking machine), Inotuzumab ozogamicin, Docetaxel, Abstract, Metastasis, RCT, Cancer, Carfilzomib, NSCLC, Denosumab, Sarcoma, Colorectal cancer, Biomarker, Busulfan, Neoplasm, Pembrolizumab, CRC, Dexamethasone, SCLC, ASCO, Talimogene laherparepvec, American Society of Clinical Oncology, ASCT, Melanoma, Annual general meeting, CDT, Melphalan, Society, Pharmaceutical industry, Medical imaging, Communications satellite, Flour, Glass wool, Vaccine, Nursing, Book, Takeda, Allotransplantation, Research

THOUSAND OAKS, Calif., June 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its diverse oncology portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 2-6 in Chicago. More than 25 abstracts from Amgen-sponsored and collaborative studies, including three oral presentations and two poster discussions, will feature data in hard-to-treat tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and small cell lung cancer (SCLC).

Key Points: 
  • Additional Analyses from DeLLphi-300 Highlight Safety and Clinical Efficacy of Tarlatamab, an Investigational First-in-Class BiTE® Immunotherapy, in Patients with SCLC With Treated and Stable Brain Metastases
    THOUSAND OAKS, Calif., June 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its diverse oncology portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 2-6 in Chicago.
  • More than 25 abstracts from Amgen-sponsored and collaborative studies, including three oral presentations and two poster discussions, will feature data in hard-to-treat tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and small cell lung cancer (SCLC).
  • "Our presentations at ASCO will illustrate how we're advancing novel approaches to address the toughest thoracic and colorectal cancers with limited treatment options," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.
  • "We're focused on expanding the reach and impact of our transformative, first-in-class medicines to help more people living with cancer."

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) IN PSORIATIC ARTHRITIS AT EULAR 2023

Retrieved on: 
Tuesday, May 30, 2023
Apremilast, Inflammation, AMGN, Amgen, Psoriatic arthritis, University, Arthritis, University of Copenhagen, Ligament, Synovitis, Clinical trial, Finger, HDL, Research, Congress, MRI, BME, Magnetic resonance imaging, HIV disease progression rates, Poster, European, Rigshospitalet, LDL, Tenosynovitis, Joint, Global Medical Device Nomenclature, Body mass index, EULAR, All India Mahila Congress, Tendon, Glycated hemoglobin, Bone erosion, Pharmaceutical industry, Medical imaging, Silviculture, Hand, Rheumatology, Patient, MOSAIC

THOUSAND OAKS, Calif., May 30, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new research examining the use of Otezla® (apremilast) in psoriatic arthritis, including the Phase 4 MOSAIC study and an exploratory analysis of cardiometabolic risk factors, which are commonly elevated in patients with psoriatic disease. The findings will be presented at the 2023 European Congress of Rheumatology (EULAR), taking place May 31-June 3 in Milan, Italy.

Key Points: 
  • The findings will be presented at the 2023 European Congress of Rheumatology (EULAR), taking place May 31-June 3 in Milan, Italy.
  • "Research presented at EULAR sheds new light on psoriatic arthritis and the role of our oral medication Otezla," said Ponda Motsepe-Ditshego, vice president, Global Medical at Amgen.
  • MOSAIC evaluated Otezla's effect on joint inflammation and structural progression of psoriatic arthritis measured by MRI.
  • "The results of this study are encouraging, as they provide important insights about Otezla treatment and its efficacy on both clinical and inflammatory manifestations of psoriatic arthritis."

Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer

Retrieved on: 
Thursday, May 18, 2023
HSV, Lymphoma, AMGN, Amgen, DNA, Kite Pharma, Senior, Harvard University, Biotechnology, Writing, MRK, Coronavirus Scientific Advisory Board, NK, Monroe Dunaway Anderson, CMO, Bangladesh Technical Education Board, MD Anderson Cancer Center, MSC, Patient, University, Bone marrow, Gambat Liver Transplant Center, Allogeneic processed thymus tissue, Biology, Merck, Entrepreneurship, Therapy, NIH, Genome, Pharmaceutical industry, Fine chemical, Replay

Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer

Key Points: 
  • Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer
    Former Chief Medical Officer of allogeneic CAR-T cell company Allogene Therapeutics and seasoned industry immuno-oncology, and cell and gene therapy expert
    Dr. Balakumaran also appointed CMO of Syena, Replay’s engineered NK cell therapy product company pioneering first-in-class engineered T-cell Receptor Natural Killer cell (TCR-NK) therapy
    San Diego, California and London, UK, May 18, 2023 – Replay, a genome writing company reprogramming biology by writing and delivering big DNA, today announced the appointment of Arun Balakumaran, M.D., Ph.D., as Chief Medical Officer (CMO), effective 22 May.
  • Dr. Balakumaran joins Replay from Allogene Therapeutics (NASDAQ: ALLO), where he served as CMO and Senior Vice president, overseeing the Company’s clinical development strategy across multiple allogeneic cell therapy programs.
  • Prior to that he was Clinical Research Medical Director at Amgen (NASDAQ: AMGN), and Medical Lead in Oncology.
  • Dr. Balakumaran began his career at the National Institutes of Health (NIH), where he was Medical Lead for the Bone Marrow Stromal Cells (MSC) Transplant Center.

AMGN LAWSUIT ALERT: Levi & Korsinsky Notifies Amgen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Friday, May 12, 2023
AMGN, CASE, LLP, Average revenue per user, Internal Revenue Service, Telephone, COST, Tax, Person, Government, Levi, Risk, CLASS, NEXT, Court, Accounting Standards Codification, Insurance, Amgen

NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Amgen Inc. ("Amgen" or the "Company") (NASDAQ: AMGN) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Amgen investors who were adversely affected by alleged securities fraud.
  • This lawsuit is on behalf of all persons who purchased or otherwise acquired Amgen common stock between July 29, 2020 and April 27, 2022, inclusive.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

AMGN FINAL DEADLINE FRIDAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Amgen Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Friday Deadline in Securities Class Action - AMGN

Retrieved on: 
Thursday, May 11, 2023
Titan, AMGN, ASC, IRS, Class, Tax, Plaintiff, Government, Risk, Advertising, Court, I-Space (Chinese company), Insurance, Tobacco, Security (finance), Amgen

WHAT TO DO NEXT: To join the Amgen class action, go to https://rosenlegal.com/submit-form/?case_id=13114 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Amgen class action, go to https://rosenlegal.com/submit-form/?case_id=13114 or call Phillip Kim, Esq.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Amgen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 12, 2023 – (NASDAQ: AMGN)

Retrieved on: 
Thursday, May 11, 2023
Amgen, AMGN, Average revenue per user, Internal Revenue Service, Tax, Person, Government, Risk, CLASS, NEXT, Accounting Standards Codification, Fraud, Holding company, Security (finance)

CLASS PERIOD: This lawsuit is on behalf of all persons who purchased or otherwise acquired Amgen common stock between July 29, 2020 and April 27, 2022, inclusive.

Key Points: 
  • CLASS PERIOD: This lawsuit is on behalf of all persons who purchased or otherwise acquired Amgen common stock between July 29, 2020 and April 27, 2022, inclusive.
  • DEADLINE: May 12, 2023 Shareholders should not delay in registering for this class action.
  • The deadline to seek to be a lead plaintiff is May 12, 2023.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amgen Inc. (AMGN)

Retrieved on: 
Thursday, May 11, 2023
Class Action Lawsuit, Professional Services, Legal, AMGN, Amgen, ASC, IRS, Tax, Law, Government, Suite, Risk, Court, Defendant, News, Cryptocurrency

The Law Offices of Frank R. Cruz reminds investors of the upcoming May 12, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Amgen Inc. (“Amgen” or the “Company”) (NASDAQ: AMGN ) common stock between July 29, 2020 and April 27, 2022, inclusive (the “Class Period”).

Key Points: 
  • The Law Offices of Frank R. Cruz reminds investors of the upcoming May 12, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Amgen Inc. (“Amgen” or the “Company”) (NASDAQ: AMGN ) common stock between July 29, 2020 and April 27, 2022, inclusive (the “Class Period”).
  • On this news, Amgen’s stock price fell $15.77, or 6.5%, to close at $228.31 per share on August 4, 2021, thereby injuring investors.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

AMGN Final Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Filed against Amgen Inc. (AMGN)

Retrieved on: 
Thursday, May 11, 2023
Pension fund, AMGN, Insurance, LLP, IRS, COPY, E pluribus unum, Lead, Government, District court, Court, News, Security (finance), Cryptocurrency, Amgen

The action charges Amgen with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points: 
  • The action charges Amgen with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • Kessler Topaz Meltzer & Check, LLP encourages Amgen investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel.
  • Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

AMGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Amgen Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, May 11, 2023
Class Action Lawsuit, Professional Services, Legal, AMGN, P.C, ASC, IRS, Telephone, Tax, Jeanne Eagels, Person, Electric Bond and Share Company v. Securities and Exchange Commission, Government, Deficiency, District court, Risk, Court, News, Cryptocurrency, Life insurance, Amgen

Investors have until May 12, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until May 12, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • Amgen is one of the world’s largest independent biopharmaceutical companies.
  • On this news, the price of Amgen common stock fell by an additional 4.3%, further damaging investors.